Aardvark Therapeutics, Inc. announced progress in its Phase 3 HERO trial for ARD-101, aimed at treating hyperphagia associated with Prader-Willi Syndrome, with data expected in early 2026. The company ...
Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA ...
(RTTNews) - Biopharmaceutical company Amgen, Inc. (AMGN) announced Monday that the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary ...
CLD-101, a neural stem cell-based oncolytic virotherapy, shows safety and feasibility in a phase 1 trial for recurrent high-grade glioma. The trial involves up to four weekly intracerebral doses, with ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ...
BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially ...
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results